Breast Cancer Research and Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer
ConclusionThis is the first study which illustrates the value of measuring circulatory miRNA to predict patient-specific toxicities to NAC. These results support the ideology that circulatory miRNAs are biomarkers with utility in predicting chemotherapy toxicity as well as treatment response. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - September 15, 2023 Category: Cancer & Oncology Source Type: research

Combining the tumor-stroma ratio with tumor-infiltrating lymphocytes improves the prediction of pathological complete response in breast cancer patients
ConclusionTSR and sTILs can be easily measured in pathological routines and provide predictive information without additional cost; with more evidence from clinical trials, TSRILs could be a candidate to better stratify patients in NAC settings. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - September 15, 2023 Category: Cancer & Oncology Source Type: research

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case –control study
ConclusionThe conventional US combined with clinicopathological characteristics to construct a combined model has a good diagnostic effect in predicting pCR in HER2-positive breast cancer and is expected to be a useful tool to assist clinicians in effectively determining the efficacy of NACT in HER2-positive breast cancer patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - September 15, 2023 Category: Cancer & Oncology Source Type: research

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2-  advanced breast cancer with impending or established visceral crisis
ConclusionIn this retrospective study, patients with ER+/HER2- ABC and IVC/VC treated with CDK4/6i had a significantly better survival compared to those treated with weekly paclitaxel. Further prospective studies that minimise possible selection bias are recommended. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - September 15, 2023 Category: Cancer & Oncology Source Type: research

Retraction Note: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - September 15, 2023 Category: Cancer & Oncology Source Type: research

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)
ConclusionThe efficacy of biweekly administration of eribulin at maintenance was nonsignificant. However, less frequent visits are convenient, and reduced dose intensity improves safety. Biweekly administration, besides dose reduction, could be an acceptable option for patients who are unable to maintain a standard regimen. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4
ConclusionOur results indicate that MEX3A plays a prominent oncogenic role in BC tumorigenesis and progression by targeting IGFBP4 mRNA and activating PI3K/AKT signaling, which can be used as a novel therapeutic target for BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer
ConclusionTargeting the “FN1/YAP1/SLC1A3/Aspartate metabolism” regulatory axis provides a new target for BC diagnosis and treatment. This study also revealed that intratumoral metabolic heterogeneity plays an important role in the progression of different subtypes of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases
ConclusionILC patients had a higher mastectomy rate, higher surgical margin rate and distant metastasis rate than IDC patients. There is no significant difference in DFS or OS between ILC and IDC patients. Mastectomy was associated with poor outcomes regardless of ILC or IDC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index
ConclusionsHigher RS was observed in younger and premenopausal breast cancer patients, especially among the Black and obese subgroups, and in non-obese patients, especially among Black and older/postmenopausal women, suggesting more aggressive disease in these subgroups. Some statistical differences could be replicated by both surrogate models, suggesting that they may have utility in breast cancer epidemiology studies that do not have access to Oncotype DX RS or patient outcome data. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

The dynamics of HER2-low expression during breast cancer progression
ConclusionsHER2-low BCs constitute a heterogeneous group of tumors. Low HER2 expression is dynamic, with significant discordance between primary tumors and advanced disease as well as the distant sites of relapse. Repeat biomarker studies from advanced disease are warranted in making appropriate treatment plans in the pursuit of precision medicine. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers
ConclusionThese data indicate that DMF ’s anti-breast cancer activities in the ER+HER2+models, at least in part, are due to inhibition of ZNF217. DMF is identified as a new covalent inhibitor of ZNF217. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?
ConclusionA TND-cut-off   ≥ 2 cm on preNAC and postNAC MRI was shown to be highly predictive of negative nipple tumor involvement. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Treatments for breast cancer in men: late effects and impact on quality of life
ConclusionOur study showed that men suffer several late effects from treatments for breast cancer. Lymphedema, difficulty with arm and shoulder movement, sexual dysfunction and hair loss should be discussed with males as it can be distressing for some patients and decrease their quality of life. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry
ConclusionLuminal ILC had a poorer prognosis than luminal IDC, contributing to the worse prognosis of ILC than that of IDC in the overall cohort. Different therapeutic approaches from luminal IDC are essential for a better prognosis of luminal ILC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research